688235 百济神州
已收盘 08-13 15:00:01
资讯
新帖
简况
百济神州（688235）披露授出受限制股份单位公告，8月13日股价下跌0.5%
证券之星 · 08-13 22:03
百济神州（688235）披露授出受限制股份单位公告，8月13日股价下跌0.5%
百济神州(06160)授出合共40764股美国存托股份受限制股份单位
智通财经 · 08-13 16:56
百济神州(06160)授出合共40764股美国存托股份受限制股份单位
研报掘金丨首创证券：维持百济神州“增持”评级，实体瘤管线临床研究加速推进
格隆汇 · 08-13 15:41
研报掘金丨首创证券：维持百济神州“增持”评级，实体瘤管线临床研究加速推进
吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！
新浪基金 · 08-11 19:25
吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！
百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用
北京商报 · 08-11 16:35
百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用
市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了
第一财经 · 08-11 12:48
市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了
浦银国际证券：上调百济神州目标价至361.4元，给予买入评级
证券之星 · 08-11 12:22
浦银国际证券：上调百济神州目标价至361.4元，给予买入评级
港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展
智通财经 · 08-11 09:42
港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展
百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用
金吾财讯 · 08-11 09:39
百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用
中金：维持百济神州(06160)跑赢行业评级 目标价266港元
智通财经 · 08-11 09:16
中金：维持百济神州(06160)跑赢行业评级 目标价266港元
百济神州与Revolution Medicines达成临床开发及区域商业化合作
格隆汇 · 08-11 07:52
百济神州与Revolution Medicines达成临床开发及区域商业化合作
百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参
每日经济新闻 · 08-11 07:01
百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参
瞄准“不可成药”靶点！百济神州与Revolution达成合作，布局RAS联合治疗赛道
每日经济新闻 · 08-11
瞄准“不可成药”靶点！百济神州与Revolution达成合作，布局RAS联合治疗赛道
百济神州与Revolution Medicines宣布临床开发及区域商业化合作
美股速递 · 08-10
百济神州与Revolution Medicines宣布临床开发及区域商业化合作
百济神州获Revolution Medicines四大资产在选定亚洲市场的独家授权
美股速递 · 08-10
百济神州获Revolution Medicines四大资产在选定亚洲市场的独家授权
百济神州与Revolution Medicines合作：里程碑付款与分级版税权益
美股速递 · 08-10
百济神州与Revolution Medicines合作：里程碑付款与分级版税权益
交银国际：百济神州(06160)目标价上调至276港元 维持“买入“评级
智通财经 · 08-10
交银国际：百济神州(06160)目标价上调至276港元 维持“买入“评级
【机构调研记录】圆信永丰基金调研百济神州
证券之星 · 08-10
【机构调研记录】圆信永丰基金调研百济神州
【机构调研记录】信达澳亚基金调研百济神州
证券之星 · 08-10
【机构调研记录】信达澳亚基金调研百济神州
【私募调研记录】岳瀚资产调研百济神州
证券之星 · 08-10
【私募调研记录】岳瀚资产调研百济神州
加载更多
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":292.18,"timestamp":1786604401000,"preClose":293.65,"halted":0,"volume":7063627,"delay":0,"changeRate":-0.005,"floatShares":114999999,"shares":1542000000,"eps":2.0509,"marketStatus":"已收盘","change":-1.47,"latestTime":"08-13 15:00:01","open":291,"high":301.96,"low":290.11,"amount":2095000000,"amplitude":0.0404,"askPrice":292.2,"askSize":322,"bidPrice":292.18,"bidSize":25,"shortable":0,"etf":0,"ttmEps":2.0509,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786671000000},"marketStatusCode":5,"adr":0,"adjPreClose":293.65,"symbolType":"stock_kcb","openAndCloseTimeList":[[1786584600000,1786591800000],[1786597200000,1786604400000]],"highLimit":323.02,"lowLimit":264.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1542285181,"isCdr":false,"pbRate":13.64,"roa":"--","peRate":142.464284,"roe":"5.05%","epsLYR":1.03,"committee":-0.782716,"marketValue":450625000000,"turnoverRate":0.0614,"status":1,"afterMarket":{"amount":1185958.62,"volume":4059,"close":292.18,"buyVolume":0,"sellVolume":620,"time":1786606437746,"indexStatus":"已收盘 08-13 15:30:00","preClose":293.65},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":219.4,"timestamp":1786608494006,"preClose":216.6,"halted":0,"volume":7273087,"delay":0,"premium":"-35.46"},"floatMarketCap":33617000000},"requestUrl":"/m/hq/s/688235","defaultTab":"news","newsList":[{"id":"2659168507","title":"百济神州（688235）披露授出受限制股份单位公告，8月13日股价下跌0.5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2659168507","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659168507?lang=zh_cn&edition=full","pubTime":"2026-08-13 22:03","pubTimestamp":1786629800,"startTime":"0","endTime":"0","summary":"截至2026年8月13日收盘，百济神州报收于292.18元，较前一交易日下跌0.5%，最新总市值为4506.25亿元。该股当日开盘291.0元，最高301.96元，最低290.11元，成交额达20.95亿元，换手率为6.14%。近日，公司披露港股公告显示，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划向三百六十二名承授人授出合计40,764股美国存托股份的受限制股份单位，相当于529,932股普通股，约占公司当前已发行股份总数的0.03%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081300039413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1500","BK0239","LU1969619763.USD","BK1583","688235","KURE","LU0828237510.HKD","LU1770034418.SGD","06160","BK1588","LU2328871848.SGD","LU0307460666.USD","LU0228659784.USD","LU1251922891.USD","LU1303224171.USD","LU0588546209.SGD","BK1161","LU1719994722.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659137609","title":"百济神州(06160)授出合共40764股美国存托股份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2659137609","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659137609?lang=zh_cn&edition=full","pubTime":"2026-08-13 16:56","pubTimestamp":1786611374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年8月7日，董事会薪酬委员会根据2016期权及激励计划的条款授予362名承授人合共40,764股美国存托股份受限制股份单位。该等受限制股份单位相当于529,932股股份，约占本公告之日公司发行股份总数的0.03%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ONC","LU1303224171.USD","BK1588","LU0307460666.USD","BK1161","06160","KURE","BK4585","BK4588","LU1719994722.HKD","BK4139","LU1770034418.SGD","LU0588546209.SGD","BK4526","BK1500","LU1969619763.USD","LU0828237510.HKD","LU2328871848.SGD","BK0239","LU1251922891.USD","688235","BK1583","LU0228659784.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659134827","title":"研报掘金丨首创证券：维持百济神州“增持”评级，实体瘤管线临床研究加速推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2659134827","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659134827?lang=zh_cn&edition=full","pubTime":"2026-08-13 15:41","pubTimestamp":1786606895,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688235","BK0239","601136","BK0276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658992720","title":"吃药行情继续上演！甘李药业涨停，百济神州6连阳！华宝基金港股通医疗ETF、港股通创新药ETF逆市三连涨！","url":"https://stock-news.laohu8.com/highlight/detail?id=2658992720","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658992720?lang=zh_cn&edition=full","pubTime":"2026-08-11 19:25","pubTimestamp":1786447500,"startTime":"0","endTime":"0","summary":"8月11月，A股、港股大幅回调，医药资产受大市影响整体冲高回落，其中创新药产业链韧性凸显，批量成功收红。成份股再鼎医药领涨5.28%，权重龙头百济神州涨2.63%斩获6连阳，股价创年内新高！基金管理人评估的药ETF华宝的风险等级为R3-中风险，适宜平衡型及以上的投资者，港股通医疗ETF华宝、港股通创新药ETF华宝及其联接基金的风险等级为R4-中高风险，适宜积极型及以上的投资者。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-11/doc-inimyaaf7389173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06160","159828","LU1719994722.HKD","LU0228659784.USD","LU1251922891.USD","FLHK","BK4139","KURE","159316","BK1588","LU2328871848.SGD","LU0588546209.SGD","BK4585","ONC","BK1161","LU0307460666.USD","LU0828237510.HKD","603087","BK1583","LU1770034418.SGD","LU1969619763.USD","688235","BK1500","BK4588","BK0239","LU1303224171.USD","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658993724","title":"百济神州宣布安泰适（注射用塔拉妥单抗）正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658993724","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658993724?lang=zh_cn&edition=full","pubTime":"2026-08-11 16:35","pubTimestamp":1786437325,"startTime":"0","endTime":"0","summary":"8月10日，由百济神州与安进公司共同负责中国（不含港澳台地区）商业化开发的安泰适（注射用塔拉妥单抗）正式投入临床使用。截至8月10日，全国17个城市29家医疗机构已开出首批处方。据悉，塔拉妥单抗为首个且目前唯一获批的靶向DLL3和CD3的T细胞衔接器（TCE），于8月7日启动供应，首批复盖全国80个城市、超200家医疗机构。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837896326.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837896326.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1583","06160","LU1251922891.USD","LU1303224171.USD","BK4526","KURE","BK0239","LU0828237510.HKD","BK1161","LU1770034418.SGD","LU0228659784.USD","LU1719994722.HKD","LU1969619763.USD","BK1500","ONC","688235","LU0307460666.USD","BK1588","BK4585","BK4588","LU0588546209.SGD","BK4139","LU2328871848.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658161961","title":"市值超4800亿元的药企股价涨逾4%: 这款“癌王”突破疗法要来中国了","url":"https://stock-news.laohu8.com/highlight/detail?id=2658161961","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658161961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:48","pubTimestamp":1786423687,"startTime":"0","endTime":"0","summary":"8月11日上午，百济神州（ONC.US、06160.HK、688235.SH）A股以及港股股价涨幅超过4%，其中A股市值达到4820亿元。盘面上，公司前一晚与RevolutionMedicines宣布达成临床开发及区域商业化合作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837721960.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837721960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2360107325.USD","KURE","IDNA","LU0348723411.USD","IE00BZ199S13.USD","LU1861215975.USD","LU0724618433.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","BK4141","LU0109394709.USD","LU0320765992.SGD","LU1251922891.USD","LU1983260115.SGD","LU1770034418.SGD","BK4605","IE00BJJMRZ35.SGD","LU1978683503.SGD","LU1854104046.USD","IE0009355771.USD","BK4585","LU1720051017.SGD","LU1720051108.HKD","BK4139","LU1548497426.USD","BBH","LU1861214812.USD","ON","LU0124384867.USD","BK1588","LU2298322129.HKD","LU2357305700.SGD","BK1583","LU0588546209.SGD","BK0239","BK4588","IE00BD6J9T35.USD","LU1854103824.USD","BK4512","IE00B2B36J28.USD","CANC","IE00BJT1NW94.SGD","06160","688235","IE0009354923.USD","LU1861219969.SGD","PTH","IE00BFMHRM44.USD","RVMD","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658842961","title":"浦银国际证券：上调百济神州目标价至361.4元，给予买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2658842961","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658842961?lang=zh_cn&edition=full","pubTime":"2026-08-11 12:22","pubTimestamp":1786422143,"startTime":"0","endTime":"0","summary":"浦银国际证券有限公司季昶阳近期对百济神州进行研究并发布了研究报告《泽布替尼远期收入重估，后续管线待验证》，上调百济神州目标价至361.4元，给予买入评级。 百济神州 维持“买入”评级，上调百济神州美股、港股、A股目标价至447.5美元、270.2港元、人民币361.4元。2Q26泽布替尼全球销售12.48亿美元，同比增长31%，其中美国销售8.93亿美元，同比增长31%。本文数据来源于浦银国际证券有限公司，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100017227.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06160","161027","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965691","title":"港股异动 | 百济神州(06160)早盘涨超4% 与Revolution Medicines达成临床合作 将加快RAS赛道开发进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965691","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965691?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:42","pubTimestamp":1786412546,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州早盘涨超4%，截至发稿，涨2.72%，报219港元，成交额2.97亿港元。消息面上，8月10日，据百济神州官微消息，公司与Revolution Medicines,Inc.宣布达成一项多方面合作协议。根据协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与Revolution Medicines四款临床阶段RAS抑制剂中任意一款或多款药物的联合治疗方案;同时，双方还达成区域授权协议，百济神州获得Revolution Medicines上述候选药物在部分亚洲市场的独家开发及商业化权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478320.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK4139","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","LU1251922891.USD","LU0228659784.USD","LU1719994722.HKD","LU0588546209.SGD","IE0009355771.USD","LU0307460666.USD","BK4526","LU1303224171.USD","IE00BJJMRZ35.SGD","BK0239","KURE","IE00B2B36J28.USD","IE0009354923.USD","BK4585","PTH","LU0109394709.USD","06160","IE00B4R5TH58.HKD","VXUS","RVMD","LU0320765992.SGD","CANC","IDNA","BBH","LU2328871848.SGD","ONC","IE00BFTCPJ56.SGD","LU1770034418.SGD","KCAI","BK1500","688235","LU1969619763.USD","LU0828237510.HKD","BK1583","BK1588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658196566","title":"百济神州（06160）盘初涨3.94% 与安进联合开发及商业化的安泰适正式投入临床使用","url":"https://stock-news.laohu8.com/highlight/detail?id=2658196566","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658196566?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:39","pubTimestamp":1786412383,"startTime":"0","endTime":"0","summary":"金吾财讯 | 百济神州 盘初上涨3.94%，最新报221.60港元，成交额1.86亿港元。消息面上，百济神州8月11日早上宣布，由百济神州与安进公司共同负责在中国开发和商业化的安泰适正式投入临床使用。此外，8月10日，百济神州宣布与Revolution Medicines达成一项多方面合作协议。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987884","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","IE0002141913.USD","IE00BJT1NW94.SGD","KURE","LU2242646821.SGD","IE00B4R5TH58.HKD","BK1583","BK4599","LU2112291526.USD","TBXU","IE00B2B36J28.USD","BK4139","SG9999001440.SGD","LU1023059063.AUD","LU2089984988.USD","BK1500","688235","06160","AMGN","LU2242652126.USD","IBB","BK4588","LU0828237510.HKD","BBH","LU0228659784.USD","LU0588546209.SGD","BK4533","BK1588","LU0289739699.SGD","LU1983299246.USD","PBE","ONC","LU0058720904.USD","IBBQ","BK4534","LU1770034418.SGD","IE0009355771.USD","BIB","BK4566","LU1061106388.HKD","BK4526","BK4585","LU1057294990.SGD","PJP","LU0109394709.USD","LU1969619763.USD","LU2468319806.SGD","BK1161","LU1571399168.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658965603","title":"中金：维持百济神州(06160)跑赢行业评级 目标价266港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2658965603","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658965603?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:16","pubTimestamp":1786410971,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持百济神州2026年和2027年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持A/H/US股目标价340元/266港币/445美元。中金主要观点如下：公司近况8月10日，百济神州与Revolution Medicines宣布达成临床开发及区域商业化合作。该合作主要涉及两个部分：1)双方将评估并开展百济神州候选药物和Revolution的四款RAS抑制剂的联合治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","688235","ONC","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658402950","title":"百济神州与Revolution Medicines达成临床开发及区域商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2658402950","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658402950?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:52","pubTimestamp":1786405930,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["688235","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950539","title":"百济神州与Revolution Medicines宣布合作；甘李药业宣布减肥新药海外BD | 医药早参","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950539","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950539?lang=zh_cn&edition=full","pubTime":"2026-08-11 07:01","pubTimestamp":1786402877,"startTime":"0","endTime":"0","summary":"丨2026年8月11日星期二丨NO.1百济神州与RevolutionMedicines宣布达成临床开发及区域商业化合作8月10日，百济神州宣布与全球专注癌症药物研发的生物科技公司RevolutionMedicines达成一项多方面合作协议，涵盖临床联合开发与区域商业化授权两大核心板块，旨在加速RAS驱动型癌症的创新疗法研发与市场落地。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113837029212.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113837029212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00BFTCPJ56.SGD","BK1500","PTH","CANC","IE00BJJMRZ35.SGD","LU0828237510.HKD","ONC","IE0009354923.USD","BK1588","159938","KURE","BK4526","06160","IE00BJT1NW94.SGD","688235","BBH","IE00B2B36J28.USD","LU0307460666.USD","IE0002141913.USD","BK4585","BK4588","603087","LU1303224171.USD","LU0320765992.SGD","IDNA","LU1969619763.USD","LU0588546209.SGD","IE00B4R5TH58.HKD","LU1719994722.HKD","LU1770034418.SGD","BK4139","RVMD","BK1574","BK1161","09939","LU0228659784.USD","BK1583","BK0239","LU2328871848.SGD","IE0009355771.USD","BK1515","BD","LU0889565916.HKD","LU1251922891.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658958697","title":"瞄准“不可成药”靶点！百济神州与Revolution达成合作，布局RAS联合治疗赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2658958697","media":"每日经济新闻","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658958697?lang=zh_cn&edition=full","pubTime":"2026-08-11 00:32","pubTimestamp":1786379520,"startTime":"0","endTime":"0","summary":"“创新药一哥”百济神州出手了。8月10日，百济神州宣布一则重磅消息：公司已经与专注于癌症药物研发的生物科技公司RevolutionMedicines达成协议，双方将开展临床合作，共同评估百济神州部分处于临床阶段的肿瘤候选药物与RevolutionMedicines四款临床阶段RAS(ON)抑制剂（RAS激活态抑制剂）中任意一款或多款药物的联合治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608113836984610.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608113836984610.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2328871848.SGD","BK4588","LU0307460666.USD","KURE","ONC","LU1969619763.USD","LU0228659784.USD","688235","BK1583","BK1500","LU1719994722.HKD","BK1588","BK0239","LU0588546209.SGD","LU0828237510.HKD","BK1161","LU1770034418.SGD","06160","BK4526","LU1251922891.USD","LU1303224171.USD","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107404036","title":"百济神州与Revolution Medicines宣布临床开发及区域商业化合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1107404036","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107404036?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:05","pubTimestamp":1786356340,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）与Revolution Medicines正式对外宣布，双方将携手推进临床开发，并达成一项区域商业化合作。这一战略联盟旨在整合双方优势资源，加速创新疗法的研发进程，同时拓展特定区域市场的商业布局。通过此次合作，两家公司有望在肿瘤等领域实现协同效应，共同应对未满足的医疗需求。合作的具体条款和涉及区域尚未完全披露，但业界普遍认为，此举将显著提升双方在精准医疗领域的竞争力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189831237","title":"百济神州获Revolution Medicines四大资产在选定亚洲市场的独家授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1189831237","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1189831237?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:05","pubTimestamp":1786356339,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）宣布，已获得Revolution Medicines, Inc.旗下四项核心资产在特定亚洲市场的独家权利。这一战略合作，标志着百济神州在亚洲关键区域的布局进一步深化。\n依据协议，百济神州将独家享有Revolution Medicines这四款创新药物在部分亚洲国家和地区的开发、商业化权益。此举不仅丰富了百济神州的肿瘤产品管线，也为其在亚洲市场的竞争力增添了强劲动力。交易的财务细节尚未披露，但市场分析人士普遍认为，此举对双方而言都是互利共赢的明智选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BJT1NW94.SGD","LU0889565916.HKD","IE0002141913.USD","IE0009355771.USD","IE00BJJMRZ35.SGD","BK0239","IE00B2B36J28.USD","IE0009354923.USD","PTH","LU0109394709.USD","IE00B4R5TH58.HKD","RVMD","LU0320765992.SGD","CANC","IDNA","BBH","IE00BFTCPJ56.SGD","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142470173","title":"百济神州与Revolution Medicines合作：里程碑付款与分级版税权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1142470173","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142470173?lang=zh_cn&edition=full","pubTime":"2026-08-10 18:04","pubTimestamp":1786356295,"startTime":"0","endTime":"0","summary":"百济神州（Beone Medicines Ltd.）与Revolution Medicines, Inc.已达成合作，根据协议，双方将在合作区域内享有获得里程碑付款及分级版税的权利。这一安排标志着两家公司在共同开发与商业化方面迈出了重要一步，为各自带来了潜在的经济收益与战略协同。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE0009354923.USD","IE00BJT1NW94.SGD","CANC","BK4139","LU0889565916.HKD","IE00BJJMRZ35.SGD","688235","IE0002141913.USD","IE0009355771.USD","IDNA","RVMD","LU0109394709.USD","IE00BFTCPJ56.SGD","LU0320765992.SGD","IE00B4R5TH58.HKD","BBH","BK0239","PTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658601016","title":"交银国际：百济神州(06160)目标价上调至276港元 维持“买入“评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2658601016","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658601016?lang=zh_cn&edition=full","pubTime":"2026-08-10 10:57","pubTimestamp":1786330638,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，交银国际发布研报称，将百济神州(06160)目标价由229.2港元上调至276港元，维持\"买入\"评级。百济神州第二季泽布替尼在适应症扩大、新患渗透加深、依从性和DoT提升等因素的推动下，再次取得超预期的销售成绩，同时替雷利珠海外开启放量通道，未来与HER2双抗联用将开辟1L HER2+胃癌治疗机会。该行上调公司2026-2028年净利预测，分别至10.26亿美元、15亿美元及20.08亿美元，以反映第二季超预期的业绩表现和最新指引。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477831.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","ONC","688235","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605964","title":"【机构调研记录】圆信永丰基金调研百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605964","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658605964?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:01","pubTimestamp":1786320105,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月7日披露的机构调研信息，圆信永丰基金近期对1家上市公司进行了调研，相关名单如下：1）百济神州 调研纪要：公司对百悦泽?圆信永丰基金成立于2014年，截至目前，资产管理规模362.35亿元，排名101/212；资产管理规模245.21亿元，排名101/212；管理公募基金数68只，排名93/212；旗下公募基金经理15人，排名90/212。旗下最近一年表现最佳的公募基金产品为圆信永丰科技驱动混合发起A，最新单位净值为2.43，近一年增长131.68%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1770034418.SGD","688235","BK1161","LU0228659784.USD","BK1500","BK0239","KURE","LU0828237510.HKD","BK1583","LU1969619763.USD","LU2328871848.SGD","LU0588546209.SGD","LU1303224171.USD","BK1588","LU1719994722.HKD","LU0307460666.USD","06160","LU1251922891.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658605962","title":"【机构调研记录】信达澳亚基金调研百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2658605962","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658605962?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:01","pubTimestamp":1786320072,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月7日披露的机构调研信息，信达澳亚基金近期对1家上市公司进行了调研，相关名单如下：1）百济神州 调研纪要：公司对百悦泽?信达澳亚基金成立于2006年，截至目前，资产管理规模1497.92亿元，排名52/212；资产管理规模851.94亿元，排名59/212；管理公募基金数197只，排名38/212；旗下公募基金经理43人，排名28/212。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU0307460666.USD","LU0228659784.USD","BK1161","LU1251922891.USD","BK1583","BK0239","LU1719994722.HKD","BK1500","06160","LU0828237510.HKD","LU0588546209.SGD","LU1770034418.SGD","LU2328871848.SGD","KURE","688235","BK1588","LU1969619763.USD","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658160596","title":"【私募调研记录】岳瀚资产调研百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2658160596","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658160596?lang=zh_cn&edition=full","pubTime":"2026-08-10 08:01","pubTimestamp":1786320066,"startTime":"0","endTime":"0","summary":"根据市场公开信息及8月7日披露的机构调研信息，知名私募岳瀚资产近期对1家上市公司进行了调研，相关名单如下：1）百济神州 调研纪要：公司对百悦泽?CEA ADC将披露肺癌早期数据，探索表达分层与共突变。公司已获得中国证券投资基金业协会的私募基金管理人资格，并成为中基协观察会员。岳瀚资产致力于打造中国资产管理行业的著名品牌，成为中国最优秀的私募基金管理公司之一。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2026081000001702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["KURE","BK1588","LU1770034418.SGD","BK1583","BK1500","06160","688235","LU0588546209.SGD","LU1719994722.HKD","BK1161","LU1969619763.USD","BK0239","LU2328871848.SGD","LU0228659784.USD","LU1251922891.USD","LU0828237510.HKD","LU1303224171.USD","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1786657076288,"stockEarnings":[{"period":"1week","weight":0.0862},{"period":"1month","weight":0.0862},{"period":"3month","weight":0.1594},{"period":"6month","weight":0.0449},{"period":"1year","weight":0.2498},{"period":"ytd","weight":0.0878}],"compareEarnings":[{"period":"1week","weight":0.0068},{"period":"1month","weight":-0.0101},{"period":"3month","weight":-0.0504},{"period":"6month","weight":-0.038},{"period":"1year","weight":0.0661},{"period":"ytd","weight":-0.0106}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35235人(较上一季度增加6.53%)","perCapita":"3265股","listingDate":"2021-12-15","address":"c/o BeOne Medicines I GmbH, Aeschengraben 27, 4051Basel, Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}